The effect of HLA-B*57:01 for the control of HIV-1 replication at viral setpoint (meaning in average 18 months after infection by HIV-1) has been demonstrated with numerous cohorts of seropositive subjects, often involving no more than 500 seropositive subjects (6, 24). Here, HLA-B is linked to infection.